No Data
No Data
shenzhen lifotronic technology co., ltd. (688389.SH): The product has obtained EU MDR certification
On October 11th, Gelonhui announced that Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) recently received a certification certificate for the EU Medical Device Regulation (EU) 2017/745, referred to as "MDR". The company's above-mentioned products have passed the CE certification under the EU MDR, indicating compliance with the latest EU medical device regulations and meeting the latest access requirements of the EU market. They can be legally sold in relevant overseas markets, which will help promote and sell the company's products in the corresponding markets.
Shenzhen Lifotronic Technology Co., Ltd. (688389.SH): Granted 11.31 million shares of stock options to 186 incentive recipients.
gelonhui september 27th: shenzhen lifotronic technology co., ltd. (688389.SH) announced that the company has determined september 26, 2024 as the grant date and granted 11.31 million shares options to 186 incentive recipients, with an exercise price of 13.80 yuan/share.
There's Been No Shortage Of Growth Recently For Shenzhen Lifotronic Technology's (SHSE:688389) Returns On Capital
Shenzhen Lifotronic Technology Co., Ltd. (688389.SH): Shareholders Liu Xiancheng, Xiamen Hanyu, etc. have reduced their shareholdings to 1%.
On September 13, Gelonhui reported that Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) announced that it received a notification letter on changes in shareholder equity from shareholders Liu Xiancheng, Xiamen Hanyu, Xiamen Qiaochuan, and Xiamen Purong on September 13, 2024. Xiamen Hanyu, Xiamen Qiaochuan, and Xiamen Purong collectively reduced their shareholding by 4,140,215 shares, accounting for 0.97% of the company's current total share capital (428,429,163 shares) from July 22, 2024, to September 13, 2024. From June 4, 2023, to September 13, 2024, due to the company's 2021,
Lifotronic Technology to Buy Stake in Medical Equipment Maker Through 16 Million Yuan Capital Injection; Shares Up 5%
Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) plans to jointly increase the capital of Sichuan Anjiechang together with the related party Liu Hongrui.
According to the company's development strategy, Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) announced that in order to further expand the market and product synergies of its clinical medical product line and improve the product portfolio of perioperative solutions, the company signed an investment agreement with Chengdu Anjiechang on May 8, 2023. Chengdu Anjiechang plans to change its business address for operational development needs, and will subsequently reorganize and integrate its assets and personnel into Sichuan Anjiechang. Therefore, the company plans to increase its capital in Sichuan Anjiechang together with related party Liu Hongrui, with a subscribed capital of 158 million yuan for Sichuan Anjiechang's new registered capital.
No Data
No Data